Farrell / McCullough / Day Non-Alcoholic Fatty Liver Disease

A Practical Guide
1. Auflage 2013
ISBN: 978-1-118-55622-1
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 328 Seiten, E-Book

Do you have patients referred to you suffering fromNAFLD?
Are you looking for an expert guide to the latest inclinical management?
If so, this is the book for you, providing an expert andcomprehensive analysis of NAFLD: what it is, why it happens, who islikely to suffer from it, and how to decide on the best managementoptions for your patients.
This book focuses clearly on providing first-rate clinicalguidance as to the assessment, diagnosis and treatment of patientsin the clinical setting, based wherever possible on the latestevidence and scientific understanding of disease mechanisms. With each chapter fully revised and updated with the very latest inAASLD, EASL and Asia-Pacific guidelines, this second editionprovides:
* Four brand new chapters, including "NAFLD andcardiovascular risk factors" and "Non-invasive methodsto determine severity of NAFLD/ NASH"
* A clear overview on the causative mechanisms of NAFLD
* Self-assessment via key points and multiple-choice questionsthroughout
* The very latest in clinical drug trials
* Analysis of NAFLD in relation to obesity, diabetes, highcholesterol and liver cancer
* A consideration of NAFLD importance in Asia (particularlyincluding Japan and China) and South America, as well as Europe andNorth America
NAFLD is a serious condition that is increasing in prevalenceglobally from year to year. Non-Alcoholic Fatty LiverDisease: A Practical Guide, is essential reading for allhepatologists and health professionals managing patients who havethis condition.

Autoren/Hrsg.

Farrell, Geoffrey C.

McCullough, Arthur J.

Day, Christopher P.

Inhaltsverzeichnis

List of Contributors, vii
1 What is non-alcoholic fatty liver disease (NAFLD), and why isit important? 1
Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P.Day
2 NAFLD in the community, 17
Leon A. Adams
3 Pathology of NAFLD, 27
Elizabeth M. Brunt and David E. Kleiner
4 The natural history of NAFLD, 37
Paul Angulo
5 Emerging concepts on the pathogenesis of non-alcoholicsteatohepatitis (NASH), 46
Isabelle A. Leclercq
6 Diabetes and NAFLD: why is the connection important? 62
Elisabetta Bugianesi
7 NAFLD and cardiovascular risk factors: implications forvascular disease, 71
Giovanni Targher
8 A primary care perspective of fatty liver: diagnosis,management, prescribing, and when to refer, 84
Shivakumar Chitturi and Geoffrey C. Farrell
9 Imaging of NAFLD, 93
Takeshi Yokoo, An Tang, and Claude B. Sirlin
10 Non-invasive methods to determine the severity of NAFLD andNASH, 112
Vincent Wai-Sun Wong and Henry Lik-Yuen Chan
11 Fatigue, quality of life, and psychosocial issues for peoplewith NAFLD, 122
Julia L. Newton and James Frith
12 Physical activity and cardiovascular fi tness in patientswith NAFLD: clinical importance and therapeutic implications,132
Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M.Byrne
13 NAFLD, obesity, and bariatric surgery, 149
Philippe Mathurin
14 Genetic predisposition to NAFLD and NASH: implications forpathogenesis, diagnosis, prevention, and management, 157
Quentin M. Anstee, Ann K. Daly, and Christopher P. Day
15 NAFLD in children, 171
Ariel E. Feldstein
16 The pointy end of the NAFLD iceberg: cirrhosis, portalhypertension, and liver failure, 182
Jonathon W. Schwake, Dawn M. Torres, and Stephen A.Harrison
17 Non-alcoholic fatty liver disease, hepatocellular cancer, andother cancers, 192
Janine Graham and Helen L. Reeves
18 NAFLD in Chinese and South Asian people, 206
Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan
19 Non-alcoholic fatty liver disease in Japan, 217
Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh
20 Non-alcoholic fatty liver disease in South America andHispanic people, 228
Helma Pinchemel Cotrim and Carla Daltro
21 Alcohol in non-alcoholic fatty liver disease: an oxymoron ora new standard of care?, 234
Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J.McCullough
22 Dietary factors in the pathogenesis and care of patients withfatty liver disease, 248
Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli,Cristiana Andruccioli, and Silvia Di Domizio
23 Metabolic factors and steatosis in patients with hepatitis Band C, 260
Francesco Negro
24 Drug therapy for NASH: insulin-sensitizing agents (metforminand thiazolidinediones), 271
Mohammad S. Siddiqui and Arun J. Sanyal
25 Hepatoprotectants against fatty liver disease: antioxidants,ursodeoxycholic acid, and herbal medicines, 284
Anne Catherine Bürgi and Jean-François Dufour
26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, andother agents, 293
Giovanni Musso, Federica Molinaro, Elena Paschetta, RobertoGambino, and Maurizio Cassader
Index, 308
Color plate section facing p86